Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Clarient Presents New Data On Insight Dx Pulmotax Assay For Lung Cancer

Clarient, a technology and services resource for pathologists, oncologists and the pharmaceutical industry, has said that data from a new study suggested that the Clarient Insight Dx Pulmotax assay might predict which lung cancer patients will respond favorably to chemotherapy.

The study, titled ‘TLE3 expression is predictive of response to chemotherapy in NSCLC,’ included 368 samples from carcinoma patients.

Clarient said that the majority of advanced-stage patients who were treated with chemotherapy received a treatment regimen containing a taxane class agent.

The Pulmotax is a single antibody immunohistochemistry test created to detect the expression of TLE3 in non-small cell lung cancer (NSCLC). Prior data have linked TLE3 expression specifically to response to taxane therapy in breast and ovarian carcinoma patients.

The study was presented at the annual meeting of the American Association of Cancer Research (AACR) in Washington, DC by Douglas T Ross, chief scientific officer of Clarient.

Alex Soltermann, the study’s principal investigator and a pathologist at the Institute of Surgical Pathology at the University Hospital Zurich, noted that for advanced NSCLC, taxane therapy is often selected as part of standard therapy; however, the inclusion of taxane carries with it an increased incidence of severe side effects which can seriously complicate patient management.

Dr Soltermann said: “In this study we saw a striking relationship between TLE3 expression in advanced lung cancer patients and response to chemotherapy in a patient population where most patients received a taxane agent as part of their treatment regimen. These results suggest that treatments may be targeted to those patients most likely to benefit from taxane therapy.”

Ron Andrews, vice chairman and chief executive officer of Clarient, said: “This marks the third tissue type where our TLE3 marker shows solid association to taxane therapy response. The consistent relationship between this diagnostic biomarker and tumor response in breast, ovarian and lung carcinoma is encouraging as it represents the potential to bring to market a product that can positively impact patient care in many different solid tumor types.